Skip to content

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

  1. Home/
  2. Media Center/
  3. Press releases /
  4. Innovative Medicine

Innovative Medicine

New Long-Term Study Suggests Lower Mortality in Alzheimer’s Patients Treated with Galantamine Versus Placebo

Significantly Lesser Cognitive Decline Also Seen in Treatment Group Compared to Placebo Group

Janssen Announces Intent Not to Enforce Patents for Darunavir in Resource-Limited Settings

Policy Aims to Support a Sustainable Supply of Medically Acceptable Generic Darunavir in Sub-Saharan Africa (SSA) and Least Developed Countries (LDC)

Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank

Lilly and Merck are First to Join Janssen in this Pre-Competitive Initiative to Increase Efficiencies in Clinical Trials

Johnson & Johnson Family of Diabetes Companies Provides Diabetes Supplies to Children in Developing Countries

LifeScan, Inc. supplies one million test strips and encourages support for International Diabetes Federation’s Life for a Child program

New Phase 3 Findings Show STELARA® Significantly Reduced Signs And Symptoms Of Active Psoriatic Arthritis

STELARA Continued to Provide Benefit in Psoriatic Arthritis Signs and Symptomsthrough Week 52 in One Phase 3 Trial

Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression In Patients With Active Rheumatoid Arthritis

Patients Receiving Intravenous Golimumab Showed Significant Improvements inSigns and Symptoms of Rheumatoid Arthritis through One Year According to New Study Findings

Efficacy and Safety Data from Phase 2B Trials of Janssen’s Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases

Data from Post Hoc Analyses of the ASPIRE and PILLAR Studies in Patients with Metavir Scores of F3 and F4 Show Sustained Viral Response Compared to Placebo